Loading clinical trials...

COMPLETEDPHASE1

Cocaine Opioid Oxytocin Option - Limited

Chronic Intranasal Oxytocin as an Adjunct to Methadone Maintenance Treatment in Patients With Co-occuring Opioid Use Disorder and Cocaine Use: A 2-week Pilot Study

NCT02028533•University of California, San Francisco

View on ClinicalTrials.gov

Summary

This is a pilot feasibility study assessing the tolerability of chronic administration of intranasal oxytocin to patients receiving methadone at an opioid replacement clinic who are actively using cocaine.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Enrolled as a patient in the San Francisco General Hospital Opioid Treatment Outpatient Program
•Stable dose of methadone for at least the past two weeks
•At least one routine urine toxicology screen positive for cocaine in the past month

Exclusion Criteria

•Positive urine pregnancy test
•Use of illicit drugs in the past month (with the exception of cocaine or cannabis)
•Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major depressive disorder with suicidal thoughts or actions
•History of psychotic or moderate-severe alcohol use disorder as defined by DSM-V criteria
•Severe neuropsychological disorder, brain trauma, epilepsy
•Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)
•Nasal obstruction, discharge, or bleeding
•Habitually drinks large volumes of water
•Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor agonists/antagonists

Locations (1)

San Francisco General Hospital Opiate Treatment Outpatient Program

San Francisco, California, United States

Key Dates

Start Date

July 1, 2014

Primary Completion Date

December 1, 2014

Completion Date

December 1, 2014

Last Updated

May 21, 2019

Enrollment

ACTUAL participants

Conditions

Opioid Use DisorderCocaine Use Disorder

Interventions

Oxytocin

DRUG

Placebo

DRUG

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177

Opioid Use DisorderOpioid Use Disorder, Moderate+1 more

View study

RECRUITINGNA

Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

NCT06843213

Opioid Use DisorderHarm Reduction+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cocaine Opioid Oxytocin Option - Limited

Inclusion Criteria

Exclusion Criteria

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

Using Facebook to Support Opioid Recovery Among American Indian Women

Social Functioning in Opioid Use Disorder

Opioid Adherence and Support Through Innovative Texting Strategies